Claims:

1. A method of treating NAFLD or NASH by administering MBX-8025 or an MBX-8025 salt.

2. MBX-8025 or an MBX-8025 salt for use in treating NAFLD or NASH.

3. The use of MBX-8025 or an MBX-8025 salt for treating NAFLD or NASH.

4. The use of MBX-8025 or an MBX-8025 salt in the manufacture of a medicament for treating NAFLD or NASH.

5. A pharmaceutical composition for treating NAFLD or NASH comprising MBX-8025 or an MBX-8025 salt.

6. A kit for treating NAFLD or NASH comprising a composition comprising MBX-8025 or an MBX-8025 salt.

7. The method, compounds, uses, composition, or kit of any one of the previous claims where the MBX-8025 or an MBX-8025 salt is MBX-8025 L-lysine dihydrate salt.

8. The method, compounds, uses, composition, or kit of any one of the previous claims where the MBX-8025 or an MBX-8025 salt is administered orally.

9. The method, compounds, uses, composition, or kit of any one of the previous claims where the daily dose of MBX-8025 or an MBX-8025 salt (when calculated as the free acid) is 20-200 mg/day, preferably 50-100 mg/day.

10. The method, compounds, uses, composition, or kit of any one of the previous claims where the MBX-8025 or an MBX-8025 salt is administered once/day.

11. The method, compounds, uses, composition, or kit of any one of the previous claims where the NAFLD or NASH is NAFLD.

12. The method, compounds, uses, composition, or kit of any one of the previous claims where the NAFLD or NASH is NASH.

Claims:

1. The use of a compound that is *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof for the manufacture of a medicament for treating a condition that is non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

2. The use of claim 1 where the compound is *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)-phenoxy)propyl)thio)-2-methylphenoxy)acetic acid l-lysine dihydrate salt.

3. The use of claim 1 or 2 where the medicament is for oral administration.

4. The use of any one of claims 1 to 3 where the daily dose of the compound is 20-200 mg when the dose of the compound is calculated as *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

5. The use of claim 4 wherein the daily dose of the compound is 50-100 mg when the dose of the compound is calculated as *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

6. The use of any one of claims 1 to 5 wherein the medicament is to be administered once/day.

7. The use of any one of claims 1 to 6 wherein the condition is non-alcoholic fatty liver disease.

8. The use of any one of claims 1 to 6 wherein the condition is non-alcoholic steatohepatitis.